IBRX280121P00005000
IBRX Jan 21 2028 5.00 Put
optionOPRA
InactiveOct 9, 2026
0.98USD+8.889%(+0.08)1Vol974OI
Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
5
Expiration
Jan 21, 2028
DTE
458d
Moneyness
OTM
Intrinsic
$0.00
IBRX 5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $0.10 | +0.00% | 1 | 256 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $0.29 | +3.57% | 172 | 4,922 |
| Mar 19, 2027 | 150d | $0.35 | +0.00% | 8 | 130 |
| Apr 16, 2027 | 178d | $0.45 | -31.82% | 2 | 3 |
| May 21, 2027 | 213d | $0.53 | -3.64% | 2 | 15 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | $1.50 | +3.45% | 5 | 40 |
| Jan 21, 2028 | 458d | $0.98 | +8.89% | 1 | 974 |
| Mar 17, 2028 | 514d | $1.50 | -7.98% | 20 | 26 |
| Jan 19, 2029 | 822d | — | — | 0 | 0 |
IBRX Nearby Strikes · Jan 21, 2028
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 2 P | $0.18 | +0.00% | 2 | 271 | OTM |
| 2.5 P | $0.23 | +15.00% | 24 | 165 | OTM |
| 3 P | $0.33 | +0.00% | 2 | 206 | OTM |
| 3.5 P | $0.55 | -73.17% | 2 | 11 | OTM |
| 4 P | $1.32 | -37.14% | 1 | 21 | OTM |
| 4.5 P | $1.35 | -38.07% | 234 | 250 | OTM |
| 5 P | $0.98 | +8.89% | 1 | 974 | OTM |
| 5.5 P | $1.58 | +17.04% | 10 | 3,931 | OTM |
| 7.5 P | $1.95 | -9.30% | 125 | 9,702 | OTM |
| 10 P | $3.50 | +3.24% | 50 | 3,806 | ITM |
| 12 P | $4.98 | -4.23% | 10 | 42 | ITM |
| 15 P | $7.25 | -14.71% | 1 | 676 | ITM |
| 17 P | $8.75 | -1.02% | 5 | 8 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.